Carregant...
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
BACKGROUND: Chk1 inhibitors are currently in clinical trials as putative potentiators of cytotoxic chemotherapy drugs. Chk1 inhibitors may exhibit single agent anti-tumor activity in cancers with underlying DNA repair, DNA damage response or DNA replication defects. METHODS: Here we describe the cel...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4137066/ https://ncbi.nlm.nih.gov/pubmed/25104095 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-570 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|